D Azambuja1, Y Natkunam2, I Biasoli3, I S Lossos4, M W Anderson2, J C Morais3, N Spector5. 1. Department of Hematology, Postgraduate Program in Internal Medicine, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 2. Department of Pathology, Stanford University School of Medicine, Stanford, USA. 3. Departments of Medicine and Pathology, University Hospital and School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 4. Department of Medicine, Division of Hematology-Oncology and Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA. 5. Departments of Medicine and Pathology, University Hospital and School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: spector@ufrj.br.
Abstract
BACKGROUND: A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL). PATIENTS AND METHODS: The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides. RESULTS: There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein-Barr virus-positive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS. CONCLUSION: CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.
BACKGROUND: A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL). PATIENTS AND METHODS: The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides. RESULTS: There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein-Barr virus-positive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS. CONCLUSION:CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.
Authors: Peter Kamper; Knud Bendix; Stephen Hamilton-Dutoit; Bent Honoré; Jens R Nyengaard; Francesco d'Amore Journal: Haematologica Date: 2010-11-11 Impact factor: 9.941
Authors: Christian Steidl; Tang Lee; Sohrab P Shah; Pedro Farinha; Guangming Han; Tarun Nayar; Allen Delaney; Steven J Jones; Javeed Iqbal; Dennis D Weisenburger; Martin A Bast; Andreas Rosenwald; Hans-Konrad Muller-Hermelink; Lisa M Rimsza; Elias Campo; Jan Delabie; Rita M Braziel; James R Cook; Ray R Tubbs; Elaine S Jaffe; Georg Lenz; Joseph M Connors; Louis M Staudt; Wing C Chan; Randy D Gascoyne Journal: N Engl J Med Date: 2010-03-11 Impact factor: 91.245
Authors: Daphne de Jong; Andreas Rosenwald; Mukesh Chhanabhai; Philippe Gaulard; Wolfram Klapper; Abigail Lee; Birgitta Sander; Christoph Thorns; Elias Campo; Thierry Molina; Andrew Norton; Anton Hagenbeek; Sandra Horning; Andrew Lister; John Raemaekers; Randy D Gascoyne; Gilles Salles; Edie Weller Journal: J Clin Oncol Date: 2007-03-01 Impact factor: 44.544
Authors: Tomás Alvaro; Marylène Lejeune; Ma Teresa Salvadó; Ramón Bosch; Juan F García; Joaquín Jaén; Alison H Banham; Giovanna Roncador; Carlos Montalbán; Miguel A Piris Journal: Clin Cancer Res Date: 2005-02-15 Impact factor: 12.531
Authors: Karl R N Baumforth; Anna Birgersdotter; Gary M Reynolds; Wenbin Wei; Georgia Kapatai; Joanne R Flavell; Emma Kalk; Karen Piper; Steve Lee; Lee Machado; Kerry Hadley; Anne Sundblad; Jan Sjoberg; Magnus Bjorkholm; Anna A Porwit; Lee-Fah Yap; Soohwang Teo; Richard G Grundy; Lawrence S Young; Ingemar Ernberg; Ciaran B J Woodman; Paul G Murray Journal: Am J Pathol Date: 2008-05-23 Impact factor: 4.307
Authors: Beatriz Sánchez-Espiridión; Ana M Martin-Moreno; Carlos Montalbán; L Jeffrey Medeiros; Francisco Vega; Anas Younes; Miguel A Piris; Juan F Garcia Journal: Haematologica Date: 2012-02-07 Impact factor: 9.941
Authors: Peter Hollander; Peter Kamper; Karin Ekstrom Smedby; Gunilla Enblad; Maja Ludvigsen; Julie Mortensen; Rose-Marie Amini; Stephen Hamilton-Dutoit; Francesco d'Amore; Daniel Molin; Ingrid Glimelius Journal: Blood Adv Date: 2017-08-08
Authors: Brian Ruffell; Alfred Au; Hope S Rugo; Laura J Esserman; E Shelley Hwang; Lisa M Coussens Journal: Proc Natl Acad Sci U S A Date: 2011-08-08 Impact factor: 11.205
Authors: Dimitry A Chistiakov; Murry C Killingsworth; Veronika A Myasoedova; Alexander N Orekhov; Yuri V Bobryshev Journal: Lab Invest Date: 2016-11-21 Impact factor: 5.662
Authors: King L Tan; David W Scott; Fangxin Hong; Brad S Kahl; Richard I Fisher; Nancy L Bartlett; Ranjana H Advani; Rena Buckstein; Lisa M Rimsza; Joseph M Connors; Christian Steidl; Leo I Gordon; Sandra J Horning; Randy D Gascoyne Journal: Blood Date: 2012-09-04 Impact factor: 22.113